This table is as of February 27, 2008 and shows the status and certain next-expected milestones of selected clinical and preclinical programs and molecules in Amgen's product pipeline. Amgen's product pipeline will change over time as programs and molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process. This table contains forward-looking statements that involve significant risks and uncertainties, including those discussed here and others that can be found in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise. From time to time, Amgen or its collaborators may issue press releases to provide updates on certain programs and milestones. Please refer to the appropriate Web sites for any such press release.

Phase 1 clinical trials investigate safety and proper dose ranges of a product candidate in a small number of human subjects.   
   
Phase 2 clinical trials investigate side effect profiles and efficacy of a product candidate in a large number of patients who have the disease or condition under study.   
   
Phase 3 clinical trials investigate the safety and efficacy of a product candidate in a large number of patients who have the disease or condition under study.   

*Program formerly identified as AMG 531.